NASDAQ:KALV KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free KALV Stock Alerts $12.09 +0.03 (+0.25%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$11.98▼$12.2150-Day Range$10.35▼$14.3852-Week Range$7.21▼$16.88Volume128,987 shsAverage Volume673,697 shsMarket Capitalization$510.05 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get KalVista Pharmaceuticals alerts: Email Address KalVista Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside106.8% Upside$25.00 Price TargetShort InterestBearish13.80% of Shares Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment-0.20Based on 5 Articles This WeekInsider TradingSelling Shares$1.07 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.05) to ($2.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.68 out of 5 starsMedical Sector220th out of 915 stocksPharmaceutical Preparations Industry91st out of 426 stocks 3.5 Analyst's Opinion Consensus RatingKalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKalVista Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about KalVista Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.80% of the outstanding shares of KalVista Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKalVista Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in KalVista Pharmaceuticals has recently increased by 5.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKalVista Pharmaceuticals does not currently pay a dividend.Dividend GrowthKalVista Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKalVista Pharmaceuticals has received a 72.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for KalVista Pharmaceuticals is -0.79. Previous Next 1.6 News and Social Media Coverage News SentimentKalVista Pharmaceuticals has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for KalVista Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for KALV on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, KalVista Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070,918.00 in company stock.Percentage Held by Insiders12.30% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about KalVista Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.05) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KalVista Pharmaceuticals is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KalVista Pharmaceuticals is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalVista Pharmaceuticals has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about KalVista Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About KalVista Pharmaceuticals Stock (NASDAQ:KALV)KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Read More KALV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KALV Stock News HeadlinesMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Masimo (MASI)May 7, 2024 | americanbankingnews.comHC Wainwright Trims KalVista Pharmaceuticals (NASDAQ:KALV) Target Price to $20.00May 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 4, 2024 | americanbankingnews.comNeedham & Company LLC Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)May 1, 2024 | finance.yahoo.comKalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal YearApril 22, 2024 | businesswire.comKalVista Pharmaceuticals Appoints William C. Fairey to Board of DirectorsApril 17, 2024 | fool.comKalVista Pharmaceuticals (NASDAQ: KALV)April 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)May 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. April 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)April 3, 2024 | businesswire.comKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 18, 2024 | finance.yahoo.comKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference AmericasMarch 12, 2024 | markets.businessinsider.comBuy Rating on KalVista Pharmaceuticals Backed by Sebetralstat’s Breakthrough in HAE TreatmentMarch 12, 2024 | finance.yahoo.comKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for SebetralstatMarch 11, 2024 | markets.businessinsider.comBuy Rating Reinforced by Strategic CEO Appointment and Promising Drug Development at KalVista PharmaceuticalsMarch 11, 2024 | businesswire.comKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational UpdateMarch 8, 2024 | finanznachrichten.deKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasMarch 8, 2024 | businesswire.comKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasMarch 7, 2024 | marketwatch.comKalVista Pharmaceuticals Stock Falls After CEO ResignsMarch 7, 2024 | markets.businessinsider.comKalVista Stock Drops After Announcement Of Resignation Of CEO Andrew CrockettMarch 7, 2024 | marketwatch.comKalVista Pharmaceuticals Names Benjamin Palleiko Chief Executive, DirectorMarch 7, 2024 | businesswire.comKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive OfficerMarch 6, 2024 | businesswire.comKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma ConferenceMarch 4, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 28, 2024 | investing.comKalVista reports high efficacy for HAE drug in phase 3 trialFebruary 27, 2024 | finance.yahoo.comKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingSee More Headlines Receive KALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/09/2024Next Earnings (Estimated)7/05/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KALV CUSIPN/A CIK1348911 Webwww.kalvista.com Phone857-999-0075Fax866-553-3269Employees118Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$35.00 Low Stock Price Target$20.00 Potential Upside/Downside+106.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.06% Return on Assets-72.65% Debt Debt-to-Equity RatioN/A Current Ratio5.44 Quick Ratio5.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book2.57Miscellaneous Outstanding Shares42,188,000Free Float36,999,000Market Cap$510.05 million OptionableOptionable Beta0.92 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Benjamin L. Palleiko (Age 58)CEO & Director Comp: $707.1kDr. Christopher M. Yea Ph.D. (Age 60)Chief Development Officer Comp: $640.23kDr. Edward P. Feener Ph.D. (Age 64)Chief Scientific Officer Comp: $506kMr. Ryan BakerHead of Investor RelationsMr. Brian Krex J.D. (Age 56)General Counsel Jarrod AldomVice President of Corporate CommunicationsMs. Rachel M. MortenSenior Vice President of Regulatory Affairs & QADr. Michael D. Smith Pharm.D. (Age 44)Senior Vice President of Development Dr. Paul K. Audhya M.B.A. (Age 51)M.D., Chief Medical Officer Ms. Nicole Sweeny (Age 48)Chief Commercial Officer More ExecutivesKey CompetitorsTravere TherapeuticsNASDAQ:TVTXAltimmuneNASDAQ:ALTOculisNASDAQ:OCSVerve TherapeuticsNASDAQ:VERVShattuck LabsNASDAQ:STTKView All CompetitorsInsiders & InstitutionsEntropy Technologies LPBought 10,172 shares on 5/8/2024Ownership: 0.024%ClariVest Asset Management LLCBought 55,561 shares on 5/7/2024Ownership: 0.132%Susquehanna Fundamental Investments LLCBought 16,179 shares on 5/7/2024Ownership: 0.038%SG Americas Securities LLCSold 125,735 shares on 5/7/2024Ownership: 0.029%BNP Paribas Financial MarketsBought 8,750 shares on 5/1/2024Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions KALV Stock Analysis - Frequently Asked Questions Should I buy or sell KalVista Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KALV shares. View KALV analyst ratings or view top-rated stocks. What is KalVista Pharmaceuticals' stock price target for 2024? 3 brokers have issued 12 month target prices for KalVista Pharmaceuticals' shares. Their KALV share price targets range from $20.00 to $35.00. On average, they predict the company's stock price to reach $25.00 in the next year. This suggests a possible upside of 106.8% from the stock's current price. View analysts price targets for KALV or view top-rated stocks among Wall Street analysts. How have KALV shares performed in 2024? KalVista Pharmaceuticals' stock was trading at $12.25 at the beginning of 2024. Since then, KALV shares have decreased by 1.3% and is now trading at $12.09. View the best growth stocks for 2024 here. Are investors shorting KalVista Pharmaceuticals? KalVista Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,520,000 shares, an increase of 12.2% from the March 15th total of 4,920,000 shares. Based on an average daily trading volume, of 809,700 shares, the short-interest ratio is currently 6.8 days. View KalVista Pharmaceuticals' Short Interest. When is KalVista Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 5th 2024. View our KALV earnings forecast. How were KalVista Pharmaceuticals' earnings last quarter? KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its quarterly earnings data on Monday, March, 11th. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.09. What other stocks do shareholders of KalVista Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE). Who are KalVista Pharmaceuticals' major shareholders? KalVista Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Rosalind Advisors Inc. (0.68%), ClariVest Asset Management LLC (0.13%), BNP Paribas Financial Markets (0.04%), Susquehanna Fundamental Investments LLC (0.04%), SG Americas Securities LLC (0.03%) and Principal Financial Group Inc. (0.02%). Insiders that own company stock include Albert Cha, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Miami Jewish Federatio Greater, Michael David Smith, Paul K Audhya, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View institutional ownership trends. How do I buy shares of KalVista Pharmaceuticals? Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KALV) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICYou need to know these two things about AI stocks ASAP…InvestorPlaceThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.